Yunnan Energy Investment (002053.SZ): The Yongning Wind Power Plant (Phase V) project has been approved by the Yunnan Provincial Development and Reform Commission.
Yunnan Energy Investment (002053.SZ) announced that it has recently received the "Approval from the Yunnan Provincial Development and Reform Commission regarding the approval of the Yongning Wind Farm (Phase V) project in Honghe Prefecture, Mile City." The Yongning Wind Farm (Phase V) project has been included in the "Yunnan Province 2025 Second Batch New Energy Project Development and Construction Plan," with the project located in Mile City, Honghe Prefecture, and a total installed capacity of 54,000 kilowatts. Before construction begins, it is necessary to handle relevant procedures for forest land, land use, environmental assessment, and other related matters in accordance with relevant laws and administrative regulations.
Yunnan Energy Investment (002053.SZ) announced that it has recently received the "Approval from the Yunnan Provincial Development and Reform Commission regarding the Approval of the Yunnan Mi Le City Yongning Wind Power Plant (Phase V) Project." The Yongning Wind Power Plant (Phase V) project has been included in the "Yunnan Province 2025 Second Batch New Energy Project Development and Construction Plan." The project is located in Mi Le City, Honghe Prefecture, with a total installed capacity of 54,000 kilowatts. Before the commencement of construction, it is necessary to complete relevant procedures such as forestry, land, and environmental impact assessments in accordance with relevant laws and administrative regulations.
Related Articles
CITIC SEC (06030) has completed the issuance of 804 million H-shares to specific investors.
HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.
STAR CM (06698) issues a profit warning, expecting the mid-term net loss attributable to shareholders to expand to approximately 38 million to approximately 46 million yuan compared to the same period last year.
CITIC SEC (06030) has completed the issuance of 804 million H-shares to specific investors.
HANSOH PHARMA (03692): HS-10582 tablets have received the clinical trial approval notice issued by the National Medical Products Administration.
STAR CM (06698) issues a profit warning, expecting the mid-term net loss attributable to shareholders to expand to approximately 38 million to approximately 46 million yuan compared to the same period last year.
RECOMMEND
